CONMED Corporation (CNMD)
Return on equity (ROE)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | 64,459 | 57,972 | 88,285 | -93,738 | -80,582 | -82,722 | -113,924 | 67,657 | 62,542 | 62,238 | 54,140 | 13,450 | 9,517 | 310 | 430 | 33,525 | 28,619 | 29,339 | 28,194 | 31,218 |
| Total stockholders’ equity | US$ in thousands | 834,222 | 796,205 | 780,194 | 752,453 | 745,545 | 716,337 | 672,968 | 789,546 | 785,435 | 755,683 | 744,499 | 725,570 | 709,038 | 683,141 | 674,898 | 701,635 | 710,467 | 700,922 | 697,009 | 693,057 |
| ROE | 7.73% | 7.28% | 11.32% | -12.46% | -10.81% | -11.55% | -16.93% | 8.57% | 7.96% | 8.24% | 7.27% | 1.85% | 1.34% | 0.05% | 0.06% | 4.78% | 4.03% | 4.19% | 4.04% | 4.50% |
December 31, 2023 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $64,459K ÷ $834,222K
= 7.73%
To analyze Conmed Corp.'s return on equity (ROE) based on the provided data, we can observe the trend over the quarters:
1. Q4 2023: ROE is 7.73%, showing a slight increase compared to the previous quarter.
2. Q3 2023: ROE is 7.28%, maintaining stability compared to the preceding quarter.
3. Q2 2023: ROE is 11.32%, indicating a significant increase in profitability.
4. Q1 2023: ROE is -12.46%, a notable decrease from the previous quarter, reflecting a negative return on equity.
5. Q4 2022: ROE is -10.81%, showing a slight improvement compared to the third quarter of 2022.
6. Q3 2022: ROE is -11.55%, indicating a slightly lower ROE compared to the second quarter of 2022.
7. Q2 2022: ROE is -16.93%, showing a significant decline in profitability.
8. Q1 2022: ROE is 8.57%, indicating a positive return on equity in the first quarter of 2022.
Overall, Conmed Corp.'s ROE has demonstrated fluctuations in profitability over the quarters, with a mix of positive and negative returns. The company experienced a notable increase in profitability in Q2 2023, following periods of negative ROE in earlier quarters. It is essential for stakeholders to further investigate the factors contributing to these fluctuations in ROE to gain a deeper understanding of the company's financial performance and future prospects.
Peer comparison
Dec 31, 2023